ArticleRadiologie (Heidelberg, Germany)2025
[Pulmonary involvement in rare systemic diseases-part 1 : Pulmonary manifestations in the context of hematological, immunological, histiocytic, and hepatological diseases and chronic inflammatory bowel disease].
Article in Radiologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary manifestations occur in a wide range of multisystemic diseases and can affect the lung parenchyma, airways, vascular system, and respiratory musculature in various ways. In particular, severe and potentially life-threatening pulmonary complications are of major concern in systemic conditions such as immunological and hematological disorders. The increasing incidence of hematological, gastrointestinal, and hepatological diseases in recent years-driven in part by lifestyle factors in Western industrialized nations-highlights the growing clinical relevance of these entities and the need for a comprehensive understanding of their pulmonary manifestations. Additional diagnostic and therapeutic challenges arise from drug-induced lung injury and late complications of therapy, such as those following stem cell transplantation.
resultsHigh-resolution computed tomography (HRCT) plays a pivotal role in this context. It allows for the early detection of characteristic pulmonary abnormalities and thus forms the basis for timely therapeutic intervention.
conclusionTargeted HRCT imaging is therefore crucial to improving clinical outcomes and preserving the quality of life in affected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.